Is Unity Software a Buy Now?
Unity Software (NYSE:U) is the company behind the popular Unity…
Sell
37
RVMD Quote, Financials, Valuation and Earnings
Last price:
$39.49
Seasonality move
:
9.25%
Day range:
$38.92 - $40.05
52-week range:
$29.17 - $62.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.54x
Volume:
2.1M
Avg. volume:
2.1M
1-year change:
1.41%
Market cap:
$7.4B
Revenue:
$11.6M
EPS (TTM):
-$4.00
Analysts' Opinion
-
Consensus RatingRevolution Medicines has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $72.36, Revolution Medicines has an estimated upside of 83.01% from its current price of $39.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $57.00 representing -44.16% downside risk from its current price of $39.54.
Fair Value
-
According to the consensus of 8 analysts, Revolution Medicines has 83.01% upside to fair value with a price target of $72.36 per share.
RVMD vs. S&P 500
-
Over the past 5 trading days, Revolution Medicines has underperformed the S&P 500 by -7.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Revolution Medicines does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Revolution Medicines revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Revolution Medicines reported revenues of --.
Earnings Growth
-
Revolution Medicines has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Revolution Medicines reported earnings per share of -$1.13.
Enterprise value:
5.3B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.43x
EV / Free cash flow:
-8.75x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $34.8M | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$275.5M | -$552.9M | -$789.4M | -$140.9M | -$240.8M | |
| EBITDA | -$265.6M | -$543.3M | -$776.6M | -$138.1M | -$237M | |
| Diluted EPS | -$3.04 | -$3.82 | -$4.00 | -$0.70 | -$1.13 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $697.4M | $534.3M | $922.8M | $1.7B | $2.1B | |
| Total Assets | $811.7M | $682.8M | $1.1B | $1.9B | $2.4B | |
| Current Liabilities | $43.8M | $57.5M | $54.6M | $93.7M | $158.6M | |
| Total Liabilities | $89.1M | $131.8M | $121M | $182.9M | $287.2M | |
| Total Equity | $722.6M | $551M | $952.2M | $1.7B | $2.1B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$231.6M | -$448.7M | -$591.3M | -$160.6M | -$194.4M | |
| Cash From Investing | -$64.1M | -$594.6M | -$322.4M | -$248M | -$15.9M | |
| Cash From Financing | $625.3M | $905.8M | $959.5M | $810K | $874K | |
| Free Cash Flow | -$242.3M | -$457.9M | -$601.7M | -$163.7M | -$197.7M | |
RVMD
Sector
Market Cap
$7.4B
$33.9M
Price % of 52-Week High
63.37%
42.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.67%
1-Year Price Total Return
1.41%
-42.23%
Beta (5-Year)
1.115
0.657
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$40.04
200-day SMA
Sell
Level
$43.88
Bollinger Bands (100)
Sell
Level
36.81 - 42.93
Chaikin Money Flow
Buy
Level
50.1M
20-day SMA
Buy
Level
$39.48
Relative Strength Index (RSI14)
Buy
Level
52.31
ADX Line
Buy
Level
17.41
Williams %R
Neutral
Level
-56.4979
50-day SMA
Buy
Level
$37.77
MACD (12, 26)
Buy
Level
0.70
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
34M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.5718)
Buy
CA Score
(Annual)
Level (-0.1251)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (0.696)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Stock Forecast FAQ
In the current month, RVMD has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RVMD average analyst price target in the past 3 months is $72.36.
-
Where Will Revolution Medicines Stock Be In 1 Year?
According to analysts, the consensus estimate is that Revolution Medicines share price will rise to $72.36 per share over the next 12 months.
-
What Do Analysts Say About Revolution Medicines?
Analysts are divided on their view about Revolution Medicines share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Revolution Medicines is a Sell and believe this share price will drop from its current level to $57.00.
-
What Is Revolution Medicines's Price Target?
The price target for Revolution Medicines over the next 1-year time period is forecast to be $72.36 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RVMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Revolution Medicines is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RVMD?
You can purchase shares of Revolution Medicines via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Revolution Medicines shares.
-
What Is The Revolution Medicines Share Price Today?
Revolution Medicines was last trading at $39.49 per share. This represents the most recent stock quote for Revolution Medicines. Yesterday, Revolution Medicines closed at $39.54 per share.
-
How To Buy Revolution Medicines Stock Online?
In order to purchase Revolution Medicines stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Uber Stock 5X?
Uber (NYSE:UBER) has generated extremely strong returns for its investors…
How High Will Bloom Energy Stock Go?
Bloom Energy (NYSE:BE) has seen its shares surge by more…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
81
SMLR alert for May 17
Semler Scientific [SMLR] is up 28.56% over the past day.
Sell
25
GLOB alert for May 17
Globant SA [GLOB] is down 23.54% over the past day.
Buy
94
HIMS alert for May 17
Hims & Hers Health [HIMS] is up 10.38% over the past day.
